IMU 5.41% 3.9¢ imugene limited

RESULTS: Forty-nine patients with a median of 4 prior lines of...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 179 Posts.
    lightbulb Created with Sketch. 47
    RESULTS: Forty-nine patients with a median of 4 prior lines of chemotherapy received at least 1 vaccination. Twenty-eight patients completed the 3 vaccination regimen. Six patients received 1 six-month boost after the regimen, and one patient received 7 six-month boosts. No serious adverse reactions or dose-limiting toxicities were observed. The vaccine was well tolerated with dose level 2 as the recommended phase II dose. The most common related toxicity in all patients was injection site reactions (24%). Two patients had a partial response (PR), 14 had stable disease (SD), and 19 had progressive disease (PD). CONCLUSIONS: The study vaccine is safe, exhibits anti-tumor activity and shows preliminary indication that peptide vaccination may avoid therapeutic resistance and offer a promising alternative to monoclonal antibody therapies.

    • Received December 7, 2018.
    • Revision received January 18, 2019.
    • Accepted February 21, 2019
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
3.9¢
Change
0.002(5.41%)
Mkt cap ! $386.7M
Open High Low Value Volume
3.6¢ 4.0¢ 3.5¢ $1.163M 31.27M

Buyers (Bids)

No. Vol. Price($)
6 2275218 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
3.9¢ 196677 3
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.